- Home
- RQI vs RAPT Comparison
RQI vs RAPT Comparison
Compare RQI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | RAPT |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RQI | RAPT |
|---|---|---|
| Price | $12.65 | $57.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $56.22 |
| AVG Volume (30 Days) | 484.2K | ★ 4.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.39 | $0.71 |
| 52 Week High | $13.39 | $58.02 |
Technical Indicators
Market Signals| Indicator | RQI | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 78.57 |
| Support Level | $12.14 | $32.00 |
| Resistance Level | $13.38 | N/A |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.08 | -0.79 |
| Stochastic Oscillator | 22.83 | 90.91 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.